GLSI - Greenwich LifeSciences shares surge 13% on robust immune response Phase IIb data in breast cancer

Greenwich LifeSciences (GLSI) announces the abstract results of the final 5 year immune response data of the Phase IIb clinical trial in metastatic breast cancer recurrences at the 2021 AACR Annual Meeting.Potent immune response data supports the previously reported clinical outcome of 0% metastatic breast cancer recurrences over 5 years of follow-up.Statistically significant peak immunity was reached after 6 months of GP2 treatment as measured in both a GP2 specific CD8 T cell dimer binding assay and a delayed-type-hypersensitivity skin test.Broad based immune response suggests that GP2 immunotherapy and Herceptin based products may also have the potential to treat other HER2 1-3+ expressing cancers.Poster showing graphs of immune response data over time will be published by AACR on Saturday, April 10th at 8:30 am ET. The Company plans to publish the poster, the abstract, and an audio recording in a joint press release on April 10th.Shares up 13% premarket trading at $55.00. GSLI stock

For further details see:

Greenwich LifeSciences shares surge 13% on robust immune response Phase IIb data in breast cancer